0001213900-26-079611.txt : 20260720 0001213900-26-079611.hdr.sgml : 20260720 20260720160506 ACCESSION NUMBER: 0001213900-26-079611 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260720 DATE AS OF CHANGE: 20260720 EFFECTIVENESS DATE: 20260720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Biotechnologies Ltd CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-591492 FILM NUMBER: 261186691 BUSINESS ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20190620 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Biotechnologies Ltd. DATE OF NAME CHANGE: 20190619 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20150122 D 1 primary_doc.xml X0708 D LIVE 0001631487 CollPlant Biotechnologies Ltd 4 OPPENHEIMER, WEIZMANN SCIENCE PARK REHOVOT L3 ISRAEL 7670104 +972 73 232 5600 ISRAEL None CollPlant Holdings Ltd. CollPlant Biotechnologies Ltd. Corporation true Yehiel Tal COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Director Chief Executive Officer and Interim Chairman of the Board of Directors Eran Rotem COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Deputy Chief Executive Officer and Chief Financial Officer Oren Fahimipoor COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Operations Philippe Bensimon COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Regulatory Affairs and Quality Assurance Jasmine Seror COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Product Development Bowman Bagley COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Commercial North America Bar Abelis COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Legal Abraham Havron COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Elan Penn COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Joseph Zarzewsky COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Hugh Evans COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Alisa Lask COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Other Health Care Decline to Disclose 06b false 2026-07-06 false true true true true Series A warrants and series B warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 FL FLORIDA NY NEW YORK TX TEXAS true 10400000 10400000 0 Including the exercise price of ordinary shares underlying such warrants at an exercise price of $0.34. The total offering amount excludes placement agent warrants (see Item 15). false 5 272000 true 0 Includes placement and management fees, $35,000 non-accountable expense allowance, reimbursement of up to $50,000 legal fees and $15,950 clearing expenses, and warrants exercisable upon shareholder approval for 458,824 ordinary shares at $0.425/share. 0 true The Company intends to use net proceeds for general corporate purposes, including working capital, R&D programs, and evaluating strategic business combinations and other strategic transactions, the amount of which cannot currently be estimated. false CollPlant Biotechnologies Ltd /s/ Eran Rotem Eran Rotem Deputy Chief Executive Officer and Chief Financial Officer 2026-07-20